A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 21, 2021

Primary Completion Date

February 26, 2022

Study Completion Date

February 26, 2022

Conditions

Healthy Participants

Interventions

DRUG

Abrocitinib

200 mg once daily (QD)

DRUG

Omeprazole

single doses of 10 mg

DRUG

Caffeine

single dose of 100 mg

DRUG

Efavirenz

single doses of 50 mg

Trial Locations (1)

Research Centers of America ( Hollywood ), Hollywood